Aarti Drugs Limited
Aarti Drugs Limited (AARTIDRUGS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
aartidrugs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 642 Cr | 606 Cr | 620 Cr | 555 Cr | 598 Cr | 557 Cr | 677 Cr | 591 Cr | 653 Cr | 602 Cr | 720 Cr | 703 Cr |
| Operating expenses (approx.) | 565 Cr | 536 Cr | 534 Cr | 490 Cr | 531 Cr | 495 Cr | 583 Cr | 516 Cr | 569 Cr | 547 Cr | 625 Cr | 605 Cr |
| EBITDA | 76 Cr | 70 Cr | 86 Cr | 65 Cr | 67 Cr | 62 Cr | 93 Cr | 74 Cr | 84 Cr | 55 Cr | 96 Cr | 98 Cr |
| OPM % | 11.9% | 11.6% | 13.8% | 11.7% | 11.2% | 11.1% | 13.8% | 12.5% | 12.9% | 9.1% | 13.3% | 14.0% |
| Other income | 0.68 Cr | 2 Cr | 1 Cr | 1 Cr | 1 Cr | 12 Cr | 2 Cr | 0.31 Cr | 0.09 Cr | 1 Cr | 0.76 Cr | 0.81 Cr |
| Interest | 8 Cr | 8 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 8 Cr | 9 Cr | 8 Cr | 9 Cr |
| Depreciation | 13 Cr | 13 Cr | 14 Cr | 13 Cr | 14 Cr | 14 Cr | 15 Cr | 15 Cr | 16 Cr | 18 Cr | 18 Cr | 18 Cr |
| Profit before tax | 56 Cr | 52 Cr | 64 Cr | 44 Cr | 46 Cr | 51 Cr | 71 Cr | 51 Cr | 60 Cr | 29 Cr | 70 Cr | 69 Cr |
| Tax % | 29.6% | 28.8% | 26.3% | 24.4% | 23.8% | 26.9% | 11.8% | -5.6% | 25.2% | -39.7% | 21.5% | 27.6% |
| Net profit | 40 Cr | 37 Cr | 47 Cr | 33 Cr | 35 Cr | 37 Cr | 63 Cr | 54 Cr | 45 Cr | 41 Cr | 55 Cr | 50 Cr |
| EPS (₹) | ₹4.29 | ₹3.99 | ₹5.15 | ₹3.62 | ₹3.83 | ₹4.06 | ₹6.88 | ₹5.91 | ₹4.95 | ₹4.44 | ₹6.05 | ₹5.49 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,561 Cr | 1,806 Cr | 2,155 Cr | 2,489 Cr | 2,716 Cr | 2,529 Cr | 2,387 Cr | 2,565 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,354 Cr | 1,544 Cr | 1,718 Cr | 2,159 Cr | 2,410 Cr | 2,212 Cr | 2,100 Cr | 2,256 Cr | Sign in for TTM |
| EBITDA | 207 Cr | 262 Cr | 437 Cr | 329 Cr | 306 Cr | 316 Cr | 287 Cr | 309 Cr | Sign in for TTM |
| OPM % | 13.3% | 14.5% | 20.3% | 13.2% | 11.3% | 12.5% | 12.0% | 12.1% | Sign in for TTM |
| Other income | 6 Cr | 1 Cr | 5 Cr | 11 Cr | 2 Cr | 4 Cr | 16 Cr | 2 Cr | Sign in for TTM |
| Interest | 40 Cr | 34 Cr | 23 Cr | 21 Cr | 33 Cr | 34 Cr | 36 Cr | 34 Cr | Sign in for TTM |
| Depreciation | 43 Cr | 49 Cr | 50 Cr | 50 Cr | 50 Cr | 51 Cr | 56 Cr | 67 Cr | Sign in for TTM |
| Profit before tax | 131 Cr | 185 Cr | 369 Cr | 270 Cr | 224 Cr | 236 Cr | 212 Cr | 211 Cr | Sign in for TTM |
| Tax % | 31.5% | 23.7% | 24.0% | 24.1% | 25.8% | 27.1% | 20.6% | 7.6% | Sign in for TTM |
| Net profit | 90 Cr | 141 Cr | 280 Cr | 205 Cr | 166 Cr | 172 Cr | 168 Cr | 195 Cr | Sign in for TTM |
| EPS (₹) | ₹38.48 | ₹60.57 | ₹30.09 | ₹22.12 | ₹17.97 | ₹18.56 | ₹18.35 | ₹21.36 | Sign in for TTM |
| Dividend payout % | — | — | — | 4.6% | 5.7% | 5.4% | 5.4% | 9.3% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 24 Cr | 23 Cr | 93 Cr | 93 Cr | 93 Cr | 92 Cr | 91 Cr | 91 Cr |
| Reserves | 520 Cr | 629 Cr | 820 Cr | 944 Cr | 1,100 Cr | 1,190 Cr | 1,278 Cr | 1,458 Cr |
| Borrowings | 471 Cr | 338 Cr | 305 Cr | 538 Cr | 607 Cr | 562 Cr | 612 Cr | 575 Cr |
| Other liabilities | 448 Cr | 586 Cr | 548 Cr | 633 Cr | 622 Cr | 588 Cr | 593 Cr | 691 Cr |
| Total liabilities | 1,463 Cr | 1,577 Cr | 1,766 Cr | 2,208 Cr | 2,421 Cr | 2,432 Cr | 2,575 Cr | 2,815 Cr |
| Fixed assets (net) | 622 Cr | 642 Cr | 659 Cr | 686 Cr | 675 Cr | 808 Cr | 856 Cr | 1,068 Cr |
| CWIP | 33 Cr | 12 Cr | 19 Cr | 77 Cr | 210 Cr | 225 Cr | 330 Cr | 214 Cr |
| Investments | 12 Cr | 13 Cr | 23 Cr | 24 Cr | 19 Cr | 20 Cr | 22 Cr | 27 Cr |
| Loans & advances | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0.24 Cr | 0.76 Cr | 0.70 Cr |
| Inventories | 247 Cr | 325 Cr | 415 Cr | 526 Cr | 516 Cr | 486 Cr | 473 Cr | 491 Cr |
| Trade receivables | 459 Cr | 489 Cr | 555 Cr | 750 Cr | 865 Cr | 705 Cr | 751 Cr | 830 Cr |
| Cash & bank | 6 Cr | 8 Cr | 10 Cr | 22 Cr | 9 Cr | 7 Cr | 5 Cr | 7 Cr |
| Other assets | 85 Cr | 87 Cr | 84 Cr | 124 Cr | 127 Cr | 182 Cr | 136 Cr | 177 Cr |
| Total assets | 1,463 Cr | 1,577 Cr | 1,766 Cr | 2,208 Cr | 2,421 Cr | 2,432 Cr | 2,575 Cr | 2,815 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 70 Cr | 134 Cr | 359 Cr | 245 Cr | 254 Cr |
| Cash from investing | — | — | — | -149 Cr | -164 Cr | -224 Cr | -165 Cr | -173 Cr |
| Cash from financing | — | — | — | 92 Cr | 17 Cr | -136 Cr | -82 Cr | -77 Cr |
| Net cash flow | — | — | — | 13 Cr | -13 Cr | -0.76 Cr | -2 Cr | 3 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -74 Cr | -30 Cr | 133 Cr | 67 Cr | 80 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019BSE balance sheet (this exchange's own filing had none for this period) | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 16.8% | 22.1% | 32.2% | 18.5% | 14.3% | 14.6% | 12.5% | 11.5% |
| ROE % | 18.4% | 24.8% | 8.6% | 22.0% | 13.9% | 13.4% | 12.3% | 12.6% |
| Debtor days | 107 | 99 | 94 | 110 | 116 | 102 | 115 | 118 |
| Inventory days | 90 | 104 | 124 | 115 | 106 | 113 | 120 | 119 |
| Days payable | 88 | 105 | 98 | 102 | 99 | 99 | 105 | 116 |
| Cash conversion cycle | 108 | 97 | 119 | 122 | 123 | 116 | 129 | 121 |
| Debt / equity | 0.87 | 0.52 | 0.33 | 0.52 | 0.51 | 0.44 | 0.45 | 0.37 |
| Current ratio | 1.33 | 1.44 | 1.78 | 1.48 | 1.60 | 1.66 | 1.60 | 1.59 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 1.96 | 1.76 | 2.12 | 1.84 |
Compare with peers
Loading peers…